July 5th, 2012

Glaxo Settlement Pulls Back Curtain On Drug Marketing

By Scott Hensley
NPR

As part of a landmark $3 billion settlement of health fraud charges by GlaxoSmithKline, the government released a slew of documents that serve as a one-stop guide to alleged sales practices that ran rampant for years.

The British drugmaker agreed to plead guilty to three misdemeanor charges. But the settlement of civil claims, Glaxo said in a statement, “does not constitute an admission of any liability or wrongdoing in the selling and marketing of Lamictal, Zofran, Imitrex, Lotronex, Flovent, Valtrex, Avandia or Advair products.”

Glaxo CEO Sir Andrew Witty said in a statement that the practices “originate in a different era for the company” and that it has turned over a new leaf.

Read more: http://www.npr.org/blogs/health/2012/07/03/156192227/glaxo-settlement-pull-back-curtain-on-drug-marketing?ps=sh_sthdl

Comments

Add your own Comment

(optional)